(Q26775860)

Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4)

PubMed

volume

24

0 references

issue

138

0 references

page(s)

630-41

0 references

cites work

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Molecular mechanisms of diverse actions of prostanoid receptors

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Updated treatment algorithm of pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Long-term therapy with inhaled iloprost in patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Beraprost therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostaglandin E2 receptor distribution and function in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Inhaled prostanoids in the therapy of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostanoid receptors in the human vascular wall.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) is a selective, pseudo-irreversible orthosteric antagonist at the prostacyclin (IP)-receptor expressed by human airway epithelial cells: IP-receptor-mediated inhibition

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its act

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

The pharmacological treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostanoid receptors: structures, properties, and functions

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Pathways in pulmonary arterial hypertension: the future is here.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

The role of combination therapy in managing pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Pulmonary arterial hypertension: the burden of disease and impact on quality of life

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor Receptor and the extracellular signaling receptor kinase 1/2 pathway

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostanoid therapies in the management of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Physiology and pathophysiology of prostanoid receptors

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Prostacyclin: an inflammatory paradox

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Synthetic Prostacyclin Analogs Differentially Regulate Macrophage Function via Distinct Analog-Receptor Binding Specificities

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1183%2F16000617.0067-2015

7 January 2021